Valuation: Aradigm Corporation

Market Cap 4.89M 4.36M 4M 3.64M 6.83M 462M 6.96M 47.8M 19.27M 244M 18.33M 17.94M 771M P/E 2016
-0.72x
P/E 2017 -9.3x
Enterprise Value 12.8M 11.43M 10.49M 9.54M 17.88M 1.21B 18.24M 125M 50.48M 640M 48.03M 47.01M 2.02B EV / Sales 2016
73.3x
EV / Sales 2017 7.27x
Free-Float
60.28%
Yield 2016 *
-
Yield 2017 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+6.73% - - 702K
-2.37%-4.19%+39.49%+63.21% 63.77B
-2.87%+0.23%+11.11%+68.89% 56.37B
+0.62%+2.60%+16.96%+103.45% 54.62B
-3.33%-7.49%+19.39%+43.57% 44.06B
-2.45%-4.33%+16.36%+99.27% 42.11B
-1.64%+0.63%+219.80%+824.67% 41B
-5.47%+39.86%+101.20%+80.57% 34.92B
+0.21%-1.23%+14.81%+47.35% 32.82B
-2.90%+17.05%-42.35%+337.41% 24.7B
Average -2.02%+7.63%+44.09%+185.38% 39.43B
Weighted average by Cap. -2.16%+5.64%+44.63%+167.82%

Financials

2016 2017
Net sales 195K 174K 160K 145K 272K 18.46M 278K 1.91M 769K 9.74M 732K 716K 30.78M 14.46M 12.91M 11.85M 10.78M 20.21M 1.37B 20.61M 142M 57.06M 723M 54.29M 53.13M 2.28B
Net income -32.94M -29.41M -26.99M -24.55M -46.02M -3.12B -46.94M -322M -130M -1.65B -124M -121M -5.2B -10.7M -9.56M -8.77M -7.98M -14.96M -1.01B -15.26M -105M -42.23M -535M -40.18M -39.32M -1.69B
Net Debt -9.37M -8.37M -7.68M -6.98M -13.1M -887M -13.36M -91.71M -36.97M -468M -35.17M -34.42M -1.48B 7.91M 7.06M 6.48M 5.9M 11.06M 749M 11.28M 77.43M 31.21M 395M 29.7M 29.07M 1.25B
Logo Aradigm Corporation
Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.
Employees
-
  1. Stock Market
  2. Stocks
  3. ARDMQ Stock